|
|
News Breaks | | | | March 7, 2013 | | 16:24 EDT |  | CHTP | Chelsea Therapeutics reports Q4 EPS (3c), consensus (8c)
Chelsea ended the year with $28.4M in cash and cash equivalents compared to $45.6M, including short-term investments, as of December 31, 2011. Chelsea anticipates that its cash and cash equivalents on hand should fund the Company's operations into the third quarter of 2014. While details for a future clinical trial for Northera are yet to be determined, this projection assumes a new trial would commence dosing in the fourth quarter of 2013. In addition to the initial costs of a new trial, assumptions underlying this guidance cover costs related to the NDA re-submission. This current forecast does not include material activities related to an NDA approval or the commercialization of Northera. | |
|
News For CHTP From The Last 14 Days Check below for free stories on CHTP the last two weeks. |
|
|
| There are no results for CHTP |
|
|
|
|
|
|
